OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology Europe
Contamination is almost always related to human error and there is a clear drive to reduce human implications in aseptic operations. This can be achieved in multiple ways.
Contamination is almost always related to human error and there is a clear drive to reduce human implications in aseptic operations. This can be achieved in multiple ways. Some solutions include:
When it comes to equipment, the main contamination risks are the contact parts, exposure risk and operator intervention, but specialised equipment, particularly barrier systems, can help to minimise all of these. Barrier systems have multiple advantages. Firstly, the operator, is kept away from the filling area by physical separation. The quality of such design has been recognised by authorities and led to significant changes in facility design. For example, isolators are usually located in ISO8 clean room instead of ISO7 clean room with all the savings attached to the simplification of the facility design and the ease of operations.
Operations such as clean-in-place (CIP) and steam-in-place (SIP)—though designed to optimise the sterility assurance level of product contact parts—remain complex and, consequently, are a source of contamination because of potential errors. Compared with these operations, the use of connectors to cross barriers and disposable sterile product paths are simple solutions to set up product path in robust aseptic conditions. In addition, containers may help to minimise contact parts. For example, the insides of ampoules, BFS and Crystal vials are never in contact with equipment contrary to vials and prefilled syringes with their respective stoppers and plungers in contact with vibrating bowls and ramps.
Length of exposure to the environment is also an issue because the probability of contaminants entering the container is higher if the exposure time is longer. On that basis, containers that require very short operating time are preferable to ones requiring longer steps. Three container bodies help minimise exposure to the environment: prefilled syringes, which are supplied sterile in tubs and immediately processed through filling and plunger placement; BFS, which is immediately filled after moulding at high temperature; and the closed vial which is kept permanently closed and immediately processed to filling and laser re-sealing. On the contrary, open classical glass vials and ampoules wait a long time fully open from the hot air tunnel to the filling and closing stations. Unfortunately for prefilled syringes, plungers, as the vial stoppers, are still exposed for long periods of time in vibrating bowls.
Another risk is operator intervention because humans are always a source of contamination. Equipment manufacturers have the task of making systems more reliable and reducing the number of steps. One recent trend in the pharma industry is to reduce the speed of filling equipment in order to minimise short stops. The result is that the output is not so affected thanks to the elimination of many short stops and the quality is improved.
The largest barrier hindering the uptake of new aseptic technologies is the pharma industry’s reluctance to use a technology that has not been approved yet. There is always a small risk that a complete drug development application using new technology will be rejected by regulators. However, this risk is minimised if both the vendor and the pharmaceutical company together build a solid scientific rationale, including robust risk analysis, to support the use of new technology. Authorities are also open to informal presentations of new technologies and, in my experience, are much more open to new technologies than many believe. It would be useful if authorities provide official advice and opinions on new technologies regarding their potential acceptability and benefit to the patient. This could significantly accelerate the development of new technologies and provide faster benefits to patients.
In the coming years, I believe that the authorities will reject more aseptic solutions which do not minimise contamination risk. Five years from now, equipment in a clean room setting may face difficulties to be approved for aseptic filling as a robust risk analysis would point out the risk of contamination due to the vicinity of the operator and the filling area . Instead, use of barrier systems and disposable technologies will continue to grow; several companies now offer fully disposable solutions for biological drugs that can be used throughout fermentation, purification, formulation and during the filling process.
Containers will also evolve; several companies have already begun to replace glass with more robust materials, such as polymers. As a result, there will be a decreased risk of small cracks, which are a significant source of contamination. Furthermore, big problems, such as the recently discovered issue of delamination with several drugs such as Erythropoietin and methotrexate, may be avoided.
Benoît Verjans is chief commercial officer of Aseptic Technologies. http://www.aseptictech.com